The gene-editing drug developer has completed its first publicly announced round to advance UC and ETH Zürich research.
Spotlight Therapeutics, a US-based gene therapy developer advancing University of California (UC) and ETH Zürich research, has raised $30m in a series A round led by GV, a corporate venturing subsidiary of conglomerate Alphabet.
The corporate was joined by undisclosed other investors, the round coming in the wake of $7.3m in equity funding in January 2018 and $6.9m in September 2019, according to regulatory filings.
Spotlight is working on cell-targeted therapeutics for cancer and a class of blood…
